| # | Country | Total Patents | |
|---|---|---|---|
| #1 | Canada | 3 | |
| #2 | United States | 3 | |
| #3 | Brazil | 2 | |
| #4 | China | 2 | |
| #5 | EPO (European Patent Office) | 2 | |
| #6 | Mexico | 2 | |
| #7 | WIPO (World Intellectual Property Organization) | 2 | |
| #8 | Hong Kong | 1 | |
| #9 | Republic of Korea | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Organic fine chemistry |
| # | Technology | |
|---|---|---|
| #1 | Medical preparations | |
| #2 | Therapeutic chemical compounds | |
| #3 | Peptides | |
| #4 | Heterocyclic compounds |
| # | Name | Total Patents |
|---|---|---|
| #1 | Pan Ke | 15 |
| #2 | Li Qiang | 10 |
| #3 | Huang Peng | 6 |
| #4 | Ke Pan | 3 |
| #5 | Qiang Li | 2 |
| #6 | Peng Huang | 2 |
| Publication | Filing date | Title |
|---|---|---|
| CN109562100A | Dopamine β-hydroxylase (DBH) inhibitor and serotonin receptor (5-HT) antagonist are used for the purposes for the treatment of cancer | |
| US2019275025A1 | Combinational uses of nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers | |
| CA2907338A1 | Base addition salts of nitroxoline and uses thereof |